Dr. William R. Gwin III is an Assistant Professor and board-certified medical
oncologist specializing in breast cancer at the University of Washington and
Fred Hutch Cancer Center. He is a principal investigator with UW Medicine’s
Cancer Vaccine Institute, where his research focuses on the development of
pre-clinical immunotherapies targeting mechanisms of resistance in
first-in-human clinical trials. He is also actively involved in the development
and oversight of clinical trials investigating novel HER2-targeted therapies. He
received his MD from the University of Alabama School of Medicine (UAB) in
2006. He went on to complete training in internal medicine at the University of
Washington, where, as a resident, he worked with Dr. Nora Disis in the CVI
investigating adoptive T-cell therapy in HER2+ breast cancer. He subsequently
was a fellow in Hematology/Oncology at Duke University Medical Center, where he
worked with Dr. Neil Spector exploring mechanisms of resistance to HER2
targeted therapies in breast cancer. As a senior medical oncology fellow, he
worked with Dr. Kim Lyerly and Dr. Mike Morse in the clinical development of
immunotherapies targeting mechanisms of therapeutic resistance in breast
cancer.
Andrew L. Coveler is an Associate Professor in the Division
of Medical Oncology at the University of Washington School of Medicine and an Associate
Member of the Clinical Research Division at Fred Hutchinson Cancer Research
Center. At the Seattle Cancer Care Alliance, he serves as director of the
Pancreas Cancer Specialty Clinic. He earned his medical degree from Northwestern
University Medical School in 2002. He also completed his internship at Baylor
College of Medicine, his internal medicine residency at the University of
Washington, and a hematology–oncology fellowship at the Fred Hutchinson Cancer
Research Center. His research encompasses trials in phase I, II ,and III; novel
agents; and immunotherapy.
